Literature DB >> 10682096

Failure of icodextrin to provide adequate ultrafiltration in continuous ambulatory peritoneal dialysis patients.

E Thodis1, P Passadakis, S Panagoutsos, D Marinopoulos, V Vargemezis.   

Abstract

Icodextrin, a starch-derived glucose polymer with an average molecular weight of 20,000 D, has been developed partly as a response to some of the disadvantages of dextrose. It has been suggested that icodextrin solutions are able to provide sustained ultrafiltration (UF) over long dwell times of 8-12 hours in continuous ambulatory peritoneal dialysis (CAPD). In this paper we describe three patients on CAPD: 2 males and 1 female aged 60, 67, and 58 years respectively, duration on CAPD 47, 60, and 15 months respectively. All of these patients, who were categorized as high transporters according to peritoneal equilibration test (PET) results, presented early signs of ultrafiltration loss with no evidence of peritoneal inflammation. Icodextrin solution was used in a single nightly exchange with 10-12 hours' dwell, for a period of 5-30 days. In all of these cases, icodextrin solution failed to provide adequate ultrafiltration and the patients returned to the previously used regime of five daily hypertonic exchanges of 3.86% glucose concentration. Although these negative results were not clearly explained, we report these three cases because they exemplify some limitations of icodextrin solution to provide adequate ultrafiltration, at least in a small number of CAPD patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10682096

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  2 in total

1.  Icodextrin re-absorption varies with age in children on automated peritoneal dialysis.

Authors:  Allison Dart; Janusz Feber; Hubert Wong; Guido Filler
Journal:  Pediatr Nephrol       Date:  2005-02-18       Impact factor: 3.714

Review 2.  Roles of the TGF-β⁻VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis.

Authors:  Hiroshi Kinashi; Yasuhiko Ito; Ting Sun; Takayuki Katsuno; Yoshifumi Takei
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.